Liminatus Pharma, Inc. Class A Common Stock (LIMN) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $0.23
• Market Cap: $7.42M
• EPS: $-0.16
• 52-Week High: $33.66
• 52-Week Low: $0.21

Market Sentiment

Liminatus Pharma, Inc. Class A Common Stock currently has a Neutral sentiment score of -0.13.

About Liminatus Pharma, Inc. Class A Common Stock

Liminatus Pharma, Inc. is a clinical-stage immuno-oncology firm based in La Palma, California, dedicated to pioneering innovative therapies for treating various cancer types. By harnessing advanced science and technology, the company focuses on addressing unmet medical needs within oncology through a robust therapeutic pipeline. With a strategic emphasis on clinical development, Liminatus is well-positioned to play a pivotal role in the evolving cancer treatment landscape, representing a comp...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Liminatus Pharma, Inc. Class A Common Stock and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does LIMN pay dividends?

Liminatus Pharma, Inc. Class A Common Stock (LIMN) does not currently pay a regular dividend.

What is LIMN's market cap?

Liminatus Pharma, Inc. Class A Common Stock (LIMN) has a market capitalization of $7.42M with a current stock price of $0.23.